| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
6.76
|
|
2
|
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
|
J Clin Oncol
|
2005
|
2.58
|
|
3
|
Breast carcinoma during pregnancy. International recommendations from an expert meeting.
|
Cancer
|
2006
|
2.04
|
|
4
|
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
|
Clin Cancer Res
|
2013
|
1.89
|
|
5
|
Treatment of breast cancer in older women.
|
Acta Oncol
|
2008
|
1.74
|
|
6
|
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
|
J Clin Oncol
|
2005
|
1.61
|
|
7
|
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
|
J Clin Oncol
|
2010
|
1.51
|
|
8
|
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.48
|
|
9
|
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
|
J Clin Oncol
|
2013
|
1.45
|
|
10
|
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
|
Breast Cancer Res Treat
|
2008
|
1.31
|
|
11
|
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
|
Breast Cancer Res Treat
|
2006
|
1.29
|
|
12
|
Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.
|
BMC Cancer
|
2005
|
1.20
|
|
13
|
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
|
J Clin Oncol
|
2007
|
1.10
|
|
14
|
Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?
|
J Clin Oncol
|
2002
|
1.04
|
|
15
|
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
|
Breast Cancer Res Treat
|
2008
|
1.00
|
|
16
|
Therapeutic management of breast cancer in the elderly.
|
Expert Opin Pharmacother
|
2011
|
0.94
|
|
17
|
Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study.
|
Tumori
|
2004
|
0.93
|
|
18
|
A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.
|
Breast Cancer Res
|
2011
|
0.92
|
|
19
|
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
|
J Clin Oncol
|
2014
|
0.91
|
|
20
|
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
|
J Clin Oncol
|
2005
|
0.87
|
|
21
|
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
|
Cancer
|
2006
|
0.85
|
|
22
|
Small tumor size and node-negative HER2-positive breast cancer: a step forward for a better treatment?
|
J Clin Oncol
|
2010
|
0.82
|
|
23
|
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.
|
Radiol Oncol
|
2013
|
0.81
|
|
24
|
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.
|
Support Care Cancer
|
2007
|
0.78
|
|
25
|
Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study.
|
Tumori
|
2010
|
0.78
|
|
26
|
Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution.
|
Tumori
|
2003
|
0.78
|
|
27
|
Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience.
|
Tumori
|
2008
|
0.78
|
|
28
|
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
|
BMC Cancer
|
2014
|
0.77
|
|
29
|
Comparison of ultrasonography, hysteroscopy, and biopsy in the diagnosis of endometrial lesions in postmenopausal tamoxifen-treated patients.
|
Acta Obstet Gynecol Scand
|
2002
|
0.77
|
|
30
|
Metabolomics biomarkers of frailty in elderly breast cancer patients.
|
J Cell Physiol
|
2014
|
0.77
|
|
31
|
Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study.
|
BMC Cancer
|
2010
|
0.77
|
|
32
|
Adjuvant therapy in elderly patients with breast cancer.
|
Clin Breast Cancer
|
2004
|
0.77
|
|
33
|
Hormonal treatment duration in elderly patients: an open question.
|
J Clin Oncol
|
2004
|
0.75
|
|
34
|
Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients?
|
Tumori
|
2009
|
0.75
|
|
35
|
Acceptance of external infusion pumps in patients with advanced breast cancer receiving continuous infusion fluorouracil.
|
Tumori
|
2004
|
0.75
|
|
36
|
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.
|
Tumori
|
2014
|
0.75
|
|
37
|
Capecitabine cardiac toxicity presenting as effort angina: a case report.
|
J Cardiovasc Med (Hagerstown)
|
2010
|
0.75
|
|
38
|
Target therapy in elderly breast cancer patients.
|
Crit Rev Oncol Hematol
|
2012
|
0.75
|
|
39
|
Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.
|
Tumori
|
2015
|
0.75
|